Antibodies, antibody pairs, and detection reagents or kits for detecting mouse interleukin-2

By developing high affinity and high specificity anti-mouse interleukin-2 rabbit-derived antibodies, the problem of low antibody specificity in the prior art was solved, and high sensitivity and accuracy detection was achieved, suitable for detecting trace murine IL-2 Protein has wide application prospects.

CN118440194BActive Publication Date: 2024-11-26WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410648932.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-23
Publication Date
2024-11-26
Estimated Expiration
2044-05-23

AI Technical Summary

Technical Problem

The specificity of antibodies used to detect interleukin-2 in the prior art is not high, resulting in limited detection sensitivity and efficiency, making it difficult to accurately monitor the occurrence, development and efficacy of the disease.

Method used

Two high affinity and high specificity anti-mouse interleukin-2 rabbit-derived antibody and antibody pairs were developed for immunoassays, with good binding activity, and can recognize different antigenic epitopes on the surface of the murine interleukin-2 protein to form a double anti-sandwich ELISA detection system.

Benefits of technology

It realizes detection of high sensitivity, specificity and accuracy, and can quantitatively detect trace levels of murine IL-2 protein, providing a reliable detection method with broad market prospects and good economic and social benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118440194B_ABST
    Figure CN118440194B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of immunological detection technology, and particularly relates to antibodies, antibody pairs and detection reagents or kits for detecting mouse interleukin-2. The antibody is a first antibody or a second antibody, and the amino acid sequences of CDR1-3 on the light chain of the first antibody are shown in SEQ ID NO.3-5, respectively, and the amino acid sequences of CDR1-3 on the heavy chain are shown in SEQ ID NO.8-10, respectively; the amino acid sequences of CDR1-3 on the light chain of the second antibody are shown in SEQ ID NO.13-15, respectively, and the amino acid sequences of CDR1-3 on the heavy chain are shown in SEQ ID NO.18-20, respectively. The antibodies and antibody pairs provided by the present invention have the ability to specifically recognize and bind to mouse interleukin-2, have high affinity for mouse interleukin-2, and have the advantages of high affinity, high sensitivity, high specificity and good accuracy for immunodetection of mouse interleukin-2.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunological detection, and in particular to an antibody, an antibody pair and a detection reagent or a kit for detecting mouse interleukin-2. Background Art

[0002] Interleukin-2, also known as interleukin-2, IL-2 or IL2, is a glycoprotein containing 169 amino acid residues with a theoretical molecular weight of about 19KD. It is a type of cell growth factor in the immune system that can regulate the cell activity of white blood cells in the immune system. Interleukin-2 is mainly synthesized by T cells (especially CD4+T cells) activated by antigens or mitogens, and is partially produced by CD8+T cells, natural killer cells (NK cells) and monocytes-macrophages. IL-2 is a highly pleiotropic cytokine that is closely related to the biological activity of different cell populations and plays an important role in the body's immune response, immune regulation and anti-tumor immunity. Human IL-2 can activate CD8+T lymphocytes and NK cells with anti-tumor activity and promote their proliferation. It is clinically used to treat metastatic melanoma and metastatic renal cancer. However, IL-2 also has the ability to activate CD4+ regulatory T cells (Treg) with immunosuppressive function, which in turn inhibits the anti-cancer immune response of T cells and may cause other toxic side effects. In addition, IL-2 is also used in the treatment of viral infections, cardiovascular diseases, liver diseases, immunodeficiency diseases and autoimmune diseases.

[0003] Since human interleukin-2 signal transduction has two opposite effects, when using drugs targeting interleukin-2 for clinical treatment, timely monitoring of interleukin-2 levels in peripheral blood and urine, or interleukin-2 levels in activated lymphocyte supernatant can provide reliable data for the occurrence and development of the disease, prognosis and efficacy observation. Therefore, the development of a highly sensitive and specific interleukin-2 protein detection method has very important medical and social significance.

[0004] At present, immunoassays based on the specific and highly sensitive reaction between antigens and antibodies, such as colloidal gold immunochromatography, latex immunochromatography, radioimmunoassay, enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA), have become the main research direction for the detection of interleukin-2 due to its low cost, strong selectivity, and large-scale operation. Different methods have their own advantages and disadvantages, but all require antibodies that specifically recognize and bind to interleukin-2. However, traditional clinical diagnosis uses mouse monoclonal antibodies, which generally have low affinity and specificity, resulting in greatly limited detection sensitivity and efficiency. Therefore, it is of great significance to develop new high-performance interleukin-2 antibodies. Summary of the invention

[0005] In view of the problems of low antibody specificity and low detection sensitivity in the prior art, the present invention provides two high-affinity and high-specificity anti-mouse interleukin-2 rabbit-derived antibodies and antibody pairs, which have the advantages of high affinity, high sensitivity, high specificity and good accuracy for immunodetection of mouse interleukin-2. Therefore, the present invention also provides the use of the aforementioned antibodies and antibody pairs in the preparation of mouse interleukin-2 detection reagents or kits, and provides detection reagents or kits containing the aforementioned antibodies and antibody pairs. The present invention is specifically implemented through the following technical solutions:

[0006] In a first aspect, the present invention provides an antibody for detecting mouse interleukin-2, selected from a first antibody or a second antibody, wherein: the amino acid sequences of CDR1-3 on the light chain variable region of the first antibody are respectively shown as SEQ ID NOs.3-5, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.8-10; the amino acid sequences of CDR1-3 on the light chain variable region of the second antibody are respectively shown as SEQ ID NOs.13-15, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.18-20.

[0007] Furthermore, the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7; the amino acid sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.17.

[0008] Furthermore, the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.6; the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.16.

[0009] Furthermore, the light chain constant region of the first antibody and the second antibody is a κ chain, and the heavy chain constant region is an IgG1 type.

[0010] Furthermore, the first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; the antigen-binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.

[0011] The second aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody or the second antibody as described above.

[0012] The third aspect of the present invention provides an antibody pair for detecting mouse interleukin-2, which consists of the first antibody and the second antibody as described above.

[0013] The fourth aspect of the present invention provides the use of the above-mentioned antibody or antibody pair for detecting mouse interleukin-2 in the preparation of a mouse interleukin-2 detection reagent or kit.

[0014] The fifth aspect of the present invention provides a detection reagent or kit for detecting mouse interleukin-2, wherein the detection reagent or kit comprises the first antibody and / or the second antibody as described above.

[0015] Furthermore, the detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, and the second antibody modified with a detectable label serves as a detection antibody.

[0016] Compared with the prior art, the advantages and positive effects of the present invention are:

[0017] The antibody containing the above CDR sequence provided by the present invention has the ability to specifically recognize and bind to mouse interleukin-2, has good binding activity, high affinity to mouse interleukin-2, and has the advantages of high affinity, high sensitivity, high specificity and good accuracy for immunodetection of mouse interleukin-2. Moreover, the two antibodies recognize different antigenic epitopes on the surface of mouse interleukin-2 protein, and can form a double antibody sandwich enzyme-linked immunosorbent assay system, which provides a feasible and reliable method for accurately and efficiently detecting trace levels of mouse IL-2 protein in samples, and has broad market prospects and good economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0019] Figure 1 The vector map used to construct the rabbit monoclonal antibody expression vector in Example 1 of the present invention, from left to right are the pBR322 vector maps carrying the light chain constant region and the heavy chain constant region;

[0020] Figure 2 This is an affinity curve diagram of the binding of rabbit monoclonal antibody 2A5 to mouse IL-2 in Example 2 of the present invention;

[0021] Figure 3 This is an affinity curve diagram of the binding of rabbit monoclonal antibody 6A12 to mouse IL-2 in Example 2 of the present invention;

[0022] Figure 4 IL-2 antigen epitope recognition curves of rabbit monoclonal antibodies 2A5 and 6A12 of Example 2 of the present invention;

[0023] Figure 5 This is the standard curve for detecting mouse IL-2 using the double antibody sandwich ELISA method established based on rabbit monoclonal antibodies 2A5 and 6A12 in Example 3 of the present invention. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0025] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.

[0026] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.

[0027] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.

[0028] The meaning of the terms "including", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B. The terms "first", "second", etc. are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that such usage can be interchangeable under appropriate circumstances.

[0029] The terms "rabbit monoclonal antibody", "monoclonal antibody", "rabbit antibody" and "rabbit monoclonal antibody" and other similar terms have the same meaning and, unless otherwise specified, refer to antibodies that specifically bind to mouse interleukin-2. The modifier "rabbit" indicates that the complementary determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence. The terms "mouse interleukin-2", "Mouse IL-2", "Mouse IL2", "Mouse interleukin-2" and other similar terms have the same meaning.

[0030] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity.

[0031] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0032] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.

[0033] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.

[0034] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.

[0035] Antibody fragments are one or more parts or fragments of a full-length antibody, which substantially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen (such as IL-2) as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2, and these antibody fragments can be obtained by conventional techniques in the art.

[0036] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a part of the heavy chain (variable region and the first constant region). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab')2 fragment and one pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Since Fab has an antigen-binding region and a part of the constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.

[0037] (ii) F(ab)2: A bivalent fragment consisting of two Fabs linked by a disulfide bridge at the hinge region.

[0038] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.

[0039] (iv) (Fv)2: consists of two Fv fragments covalently linked together.

[0040] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.

[0041] (vi) The sc(Fv)2 fragment is composed of two heavy chain variable regions and two light chain variable regions connected via a linker or the like.

[0042] In some embodiments, the full-length sequence of the antibody or antibody fragment of the present invention may include a complementary determining region (CDR) and a framework region (FR) from a rabbit immunoglobulin sequence. In other embodiments, the antibody may include amino acid residues encoded by non-rabbit immunoglobulin sequences, for example, mouse-derived antibodies, chimeric antibodies, etc., to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "mouse-derived antibody" is a chimeric antibody of a non-mouse antibody such as a rabbit antibody's CDR region and a mouse FR region. In some cases, the variable region of a non-mouse antibody is combined with a mouse antibody's constant region, such as a mouse-rabbit chimeric antibody; in other cases, the CDR region of a non-mouse antibody is combined with a FR region and a constant region derived from a mouse antibody sequence, that is, the CDR region of a non-mouse antibody is grafted onto a mouse antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other mouse antibody variable region framework sequences. In the present invention, the CDR region in the chimeric antibody or murinized antibody is derived from a rabbit CDR region.

[0043] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.

[0044] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.

[0045] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0046] The embodiment of the present invention provides an antibody for detecting mouse interleukin-2, wherein the antibody is selected from a first antibody or a second antibody, wherein the first antibody and the second antibody both include a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), which are named CDR1, CDR2 and CDR3, respectively; wherein: the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region of the first antibody are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO. Shown in NO.20.

[0047] The antibody containing the above CDR sequence provided by the present invention has the ability to specifically recognize and bind to mouse interleukin-2, and has good binding activity and high affinity for mouse interleukin-2. The affinity constant K of the first antibody is D 7.31×10 - 10 M, affinity constant K of the second antibody D 1.48×10 -9M, for immunodetection of mouse interleukin-2, has the advantages of high affinity, high sensitivity, high specificity and good accuracy. In addition, the two antibodies provided by the present invention can recognize different antigenic epitopes on the surface of mouse interleukin-2 protein, and can be used to develop a double antibody sandwich enzyme-linked immunosorbent (ELISA) detection system, which has good detection specificity and extremely high detection sensitivity. Taking the first antibody as the capture antibody and the second antibody as the detection antibody as an example, quantitative detection of IL-2 of different concentrations is performed, and its detection limit is as low as 54.85pg / mL, which provides a feasible and reliable method for accurately and efficiently detecting trace levels of mouse IL-2 protein in samples, and has broad market prospects and good economic and social benefits.

[0048] Optionally, the light chain variable region and the heavy chain variable region each include 4 framework regions (FRs), and the 4 FRs and 3 CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7. The amino acid sequence of the light chain variable region (VL) of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.17.

[0049] Optionally, the first antibody and the second antibody further include a light chain constant region and a heavy chain constant region, wherein CL and VL in each antibody constitute a light chain, and CH and VH constitute a heavy chain. The constant region of an antibody can usually be obtained through public inquiries, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa C reign to obtain CL. Specifically, the amino acid sequence of the light chain (FL chain) of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain (FH chain) is shown in SEQ ID NO.6. The amino acid sequence of the light chain (FL chain) of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain (FH chain) is shown in SEQ ID NO.16. Among them, the light chain constant region of the first antibody and the second antibody is a κ chain, and the heavy chain constant region is an IgG1 type.

[0050] Optionally, the first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; the antigen-binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.

[0051] Yet another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody and / or the second antibody as described above.

[0052] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.

[0053] The sequence of the nucleic acid molecule can be obtained by conventional means such as deduction of codon coding rules based on the amino acid sequence of the antibody. The full-length sequence of the nucleic acid molecule or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then transfected into a host cell, and the transfected host cell is cultured under specific conditions to express the antibody of the present invention.

[0054] The original vector for constructing the recombinant vector is various vectors conventional in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids, viral vectors, bacteriophages, cosmids and minichromosomes. Plasmids are the most common vector forms, and therefore, in the context of the present invention, vectors and plasmids are used interchangeably. The vector can be a cloning vector (i.e., used to transfer the nucleic acid molecule to a host and multiply in a host cell) or an expression vector (i.e., containing necessary genetic elements to allow the nucleic acid molecule inserted into the vector to be expressed in a host cell). The nucleic acid molecule of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule. This is a known technology and will not be described in detail herein.

[0055] The nucleic acid molecules encoding the heavy and light chains of the antibodies of the present invention can be constructed into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy and light chains are expressed in different host cells, each chain can be separated from the host cells expressing them, and the separated heavy and light chains are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules encoding the heavy and light chains of the rabbit antibodies of the present invention can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy and light chains can be operably connected to different promoters, or the nucleic acid sequences encoding the heavy and light chains can be operably connected to a single promoter, so that both the heavy and light chains can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.

[0056] In the present invention, the recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth phase and treated with CaCl2 or MgCl2; or by microinjection, electroporation or liposome packaging. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging, etc.

[0057] The host cell can be a prokaryotic or eukaryotic cell. Representative examples include: Escherichia coli, Streptomyces, Salmonella typhimurium, yeast, Drosophila S2 or Sf9 cells, mammalian CHO, COS7, 293 series cells, etc. After obtaining the host cell transfected or transformed with the recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain purified antibody.

[0058] Preferably, the recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).

[0059] Another embodiment of the present invention provides an antibody pair for detecting mouse interleukin-2, which is composed of the first antibody and the second antibody as described above.

[0060] The first antibody and the second antibody provided by the present invention bind to different epitopes on the surface of mouse IL-2, and are used to develop a double antibody sandwich enzyme-linked immunosorbent assay system for mouse IL-2 protein. The system has the advantages of high specificity, high sensitivity, and good reliability, and is conducive to the efficient and accurate detection of mouse IL-2 levels. The detection linear range is wide and the application scenarios are wide.

[0061] Another embodiment of the present invention provides the use of the above-mentioned antibody or antibody pair for detecting mouse interleukin-2 in the preparation of a mouse interleukin-2 detection reagent or kit.

[0062] The advantages of using the antibody or antibody pair for detecting mouse interleukin-2 in preparing a mouse interleukin-2 detection reagent or kit are the same as the advantages of the antibody or antibody pair for detecting mouse interleukin-2 over the prior art as described above, and will not be repeated here.

[0063] Based on the same inventive concept as above, an embodiment of the present invention further provides a detection reagent or kit for detecting mouse interleukin-2, wherein the detection reagent or kit comprises the first antibody and / or the second antibody as described above.

[0064] It should be emphasized that the first antibody and the second antibody can be used separately, together, or in pairs. When detecting, if used separately or together, the first antibody and / or the second antibody are used as a primary antibody or a capture antibody, the sample to be tested is contacted with the first antibody and / or the second antibody, and then the antibody is detected. In some embodiments, the first antibody and / or the second antibody can be coupled to a detectable label, and the qualitative or quantitative detection of IL-2 is achieved by analyzing the changes in the identifiable signal generated by the detectable label. In other embodiments, the first antibody and / or the second antibody (as a primary antibody or a capture antibody) against mouse IL-2 is not labeled, and the detectable label is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-mouse IL-2 antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a change in the identifiable signal by coupling the detectable labeled secondary antibody. When used in pairs, one of the first antibody and the second antibody is used as a primary antibody or a capture antibody, and the other is used as a secondary antibody or a detection antibody.

[0065] The above-mentioned detection method adopts common immunological methods, including but not limited to: enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), immunoblotting (WB), flow cytometry (FC), etc. The detection objects include recombinantly expressed IL-2, naturally secreted or expressed IL-2 protein. The detection samples include but are not limited to IL-2 protein in serum, plasma, urine, cell culture fluid, etc.

[0066] Preferably, the detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody (or primary antibody), the second antibody serves as a detection antibody (or secondary antibody), and the second antibody is modified with a detectable label.

[0067] The above-mentioned detectable labels for generating identifiable signal changes include, but are not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.

[0068] Preferably, the detectable label is biotin.

[0069] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.

[0070] Example 1 Preparation of rabbit monoclonal antibodies

[0071] The antigen of the present invention is a full-length extracellular region of high-quality recombinant MouseIL-2 (from ABclonal, item number RP01384) with biological activity obtained by expressing a mammalian expression system, and its protein sequence is shown in NCBI accession number: NP_032392.1. The antibody preparation method is a monoclonal antibody development technology based on single B lymphocyte screening and culture. Briefly, B lymphocytes are first sorted and cultured from rabbit spleen cells immunized with antigens, and then RNA in antigen-specific B lymphocytes is extracted, reverse transcribed into cDNA, and PCR amplification is performed to obtain naturally paired heavy chain variable region (VH) and light chain variable region (VL) genes encoding rabbit antibodies, and finally VH and VL genes are loaded onto expression vectors, co-transformed or transfected into host cells and cultured, and two strains of highly specific and high-affinity rabbit antibodies 2A5 and 6A12 that recognize and bind to mouse IL-2 are obtained by separation, purification, and screening. The amino acid (AA) sequences of antibodies 2A5 and 6A12 are shown in Tables 1-2, respectively. For convenience of description below, light chain CDR1-3 are represented by LCDR1, LCDR2 and LCDR3, respectively, and heavy chain CDR1-3 are represented by HCDR1, HCDR2 and HCDR3, respectively.

[0072] Table 1 Sequence information of rabbit monoclonal antibody 2A5 in this example

[0073]

[0074] Table 2 Sequence information of rabbit monoclonal antibody 6A12 in this example

[0075]

[0076]

[0077] The preparation method of rabbit antibody 2A5 and antibody 6A12 specifically includes the following steps:

[0078] 1. Animal immunization: Two New Zealand white rabbits were immunized with MouseIL-2; 200 μg of MouseIL-2 was administered to each rabbit. Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to prepare an emulsion, which was injected subcutaneously at multiple points on the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to prepare an emulsion every 3 weeks, which was injected subcutaneously at multiple points on the rabbit's abdomen and back for two booster immunizations; after three immunizations, rabbit serum samples were collected, and their titers against IL-2 were determined by ELISA. Rabbits with high serum titers were selected and booster immunized once with 200 μg of the immunogen injected subcutaneously at multiple points. Three days later, the animals were sacrificed and their spleens were taken.

[0079] 2. Isolate B lymphocytes from the spleen and sort B lymphocytes: Use conventional methods to isolate B lymphocytes from the spleen, and sort out antigen-specific B lymphocytes. For related methods, please refer to the patent "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and the patent "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".

[0080] 3. Cloning of the gene encoding rabbit monoclonal antibody: The cultured B lymphocyte supernatant was used to identify positive clones by antigen-coated ELISA. The positive clone cells were collected and lysed and then analyzed by Quick-RNA TMRNA was extracted according to the instructions of MicroPrep kit (purchased from ZYMO, item number R1051) and reverse transcribed into cDNA. The reverse transcription system includes: Oligo (dT) 12-18 primer (Life) 1 μL, dNTPs (10 mM) 1 μL, RNA 1 μL; after 65 ° C, 5 min in the PCR instrument, 5 × FS Buffer (from ABconal) 4 μL, DTT (100 mM) 1 μL, RNase OUT (40 U / μL) 1 μL, ABScript Ⅱ RT (200 U / μL, from ABconal) 1 μL were added to the above products, mixed and reacted at 42 ° C, 1 h, 85 ° C, 5 min to obtain cDNA. Using the above cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone by PCR and sequenced. The sequencing work was completed by Jinkairui Biotechnology Co., Ltd. The PCR reaction system included: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O; the PCR amplification program included: 98°C pre-denaturation for 30 s, followed by 40 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min, and the resulting reaction solution was stored at 4°C. The primer sequences (5'-3') for amplifying VL and VH genes are as follows, where F and R represent forward and reverse primers, respectively:

[0081] VL-F: tgaattcgagctcggtacccATGGACACGAGGGCCCCCAC (see SEQ ID NO. 21);

[0082] VL-R: cacacacgatggtgactgTTCCAGTTGCCACCTGATCAG (see SEQ ID NO. 22);

[0083] VH-F: tgaattcgagctcggtacccATGGAGACTGGGCTGCGCTG (see SEQ ID NO. 23);

[0084] VH-R: gtagcctttgaccaggcagcCCAGGGTCACCGTGGAGCTG (see SEQ ID NO. 24).

[0085] 4. Production and purification of rabbit monoclonal antibodies: In order to mass-produce antibodies against mouse IL-2, the mammalian expression vector pBR322 (pBR322 OSLIC Hc) carrying the light chain constant region (CL) and heavy chain constant region (CH) genes was linearized with XbaI and NheI restriction enzymes respectively. The VL and VH genes containing the signal peptide amplified by the above PCR were purified and then constructed into the above expression vectors by homologous recombination to obtain light chain gene and heavy chain gene expression vectors. The expression vectors were successfully constructed and verified by sequencing. The expression map of the vector used is shown in Figure 1 , pBR322 origin and f1 origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40 PAterminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left), Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right). CL and CH genes were obtained by searching the IMGT online database (www.imgt.org) to obtain CH from rabbit IgG gamma C reign, and CL from rabbit IgG Kappa C reign.

[0086] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" or "MDTRAPTQLLGLLLLWLPGARC", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".

[0087] The expression vectors containing the light chain (FL) gene and the heavy chain (FH) gene verified by sequencing were transfected into 293F cells together. After transfection, the cells were cultured for 72-96 hours to obtain the culture supernatant containing the recombinant rabbit monoclonal antibody that recognizes mouse IL-2. The target antibody was purified from the culture supernatant using protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100). Using 12% SDS-PAGE gel electrophoresis for detection, the concentration of antibody 2A5 was 2.3 mg / mL, and the concentration of antibody 6A12 was 2.44 mg / mL, and the purity was greater than 95%. The purified antibodies were divided and stored at -20°C for later use.

[0088] Example 2 Performance test of rabbit monoclonal antibodies 2A5 and 6A12 in recognizing IL-2 antigen

[0089] 1) The affinity of the anti-mouse IL-2 antibodies 2A5 and 6A12 obtained above to the Mouse IL-2 protein was accurately measured using the Probe Life Gator biomolecular interaction analyzer, where the concentration of antibody 2A5 was 1 μg / mL and the concentration of antibody 6A12 was 4 μg / mL; the antibodies were fixed on protein A probes, and then the recombinant Mouse IL-2 protein at two concentrations of 75 nM and 150 nM was used to bind to the antibody 2A5 and antibody 6A12, respectively, to obtain affinity curves.

[0090] Figure 2-3 The affinity curves of antibodies 2A5 and 6A12 binding to mouse IL-2 are shown respectively, where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, the abscissa represents the binding time, the dark gray curve is the real-time binding value curve, and the light gray curve is the fitted average curve. The affinity constants calculated by curve fitting are shown in Table 3, where the dissociation coefficient K off The constant used to characterize the dissociation rate of antibody and antigen, the binding coefficient K on A constant used to characterize how quickly an antibody binds to its target, the affinity constant K D K off / K on The above results show that the affinity constants K between antibodies 2A5 and 6A12 and mouse IL-2 protein are D They are 7.31×10 -10 M and 1.48×10 -9 M, confirming that the antibody has high affinity and good specificity.

[0091] Table 3 Affinity-related parameter determination results of rabbit monoclonal antibodies

[0092] Antibody <![CDATA[K off (1 / s)]]> <![CDATA[K on (1 / Ms)]]> <![CDATA[K D (M)]]> 2A5 <![CDATA[1.01×10 -3 ]]> <![CDATA[1.38×10 6 ]]> <![CDATA[7.31×10 -10 ]]> 6A12 <![CDATA[6.69×10 -4 ]]> <![CDATA[4.52×10 5 ]]> <![CDATA[1.48×10 -9 ]]>

[0093] 2) Identification of antigen recognition epitopes: The epitopes of the anti-mouse IL-2 antibodies 2A5 and 6A12 obtained above that recognize Mouse IL-2 protein were identified using the ProbeLife Gator biomolecular interaction analyzer. The material used was HFC (Anti-HIgGFC, purchased from Gator, catalog number 160003) at a concentration of 3 μg / mL. The concentrations of the antibodies 2A5 and 6A12 to be tested were both 3 μg / mL.

[0094] Figure 4The figure shows the antigen epitope recognition of mouse IL-2 by 2A5 and 6A12, where the ordinate represents the change in thickness of the conjugate after the probe binds to the antibody and protein, and the abscissa represents the binding time. As can be seen from the figure, the probe after solidifying MouseIL-2 can continue to bind to the antibody 6A12 after binding to the antibody 2A5, confirming that 2A5 and 6A12 bind to different parts of the MouseIL-2 protein surface, and the two recognize different epitopes and do not interfere with each other. Therefore, antibodies 2A5 and 6A12 can be used as paired antibodies for double antibody sandwich enzyme-linked immunosorbent assay.

[0095] Example 3 Establishment of a double antibody sandwich ELISA system based on antibodies 2A5 and 6A12 and its sensitivity test

[0096] A double antibody sandwich enzyme-linked immunosorbent assay (ELISA) system was established using 2A5 as the capture antibody and 6A12 as the detection antibody. The steps are as follows: 1) Coating the capture antibody 2A5: dilute the antibody 2A5 to 2 μg / mL with 1×PBS, mix it with a vortexer, add it to a 96-well microplate at 100 μL / well, cover it with a cover film, and incubate it in a 4°C refrigerator for 16-20 hours; 2) Washing the plate: after the incubation is completed, discard the liquid in the well, wash the plate once with 1×PBST, add 350 μL of the sample, let it stand for 40 seconds, then discard the liquid in the well, and pat the liquid in the well dry on a flat paper; 3) Blocking: Add E013 blocking solution (1×PBS containing 2% BSA, 5% sucrose, 0.05% Tween and 0.1% proclin 30 0, pH7.2) was added to the plate wells at 200 μL / well, covered with a cover film, and blocked at 37°C for 2h. After blocking, the blocking solution was discarded, the ELISA plate was patted dry, placed in a 37°C oven for drying for 0.5-2h, and taken out for use; 4) Adding antigen protein IL-2: Mouse IL-2 protein was gradiently diluted with E013 blocking solution, and the dilution concentrations were: 4000, 2000, 1000, 500, 250, 125, 62.5, and 0pg / mL. Then, different concentrations were added to the ELISA plate at 100 μL / well in sequence, covered with a cover film, and incubated at 37°C for 2h; 5) Washing the plate: After incubation, the liquid in the well was discarded, and the plate was washed three times with 1×PBST, 300 μL of sample was added, and the liquid in the well was discarded after standing for 40s, and the plate was printed on a flat paper. Pat the liquid in the well dry; 6) Add detection antibody 6A12: dilute the rabbit monoclonal antibody 6A12 (6A12-biotin) labeled with biotin to 0.083 μg / mL, add 100 μL / well to the ELISA plate, cover with a cover film, and incubate at 37°C for 1 hour; wherein, the 6A12-biotin treatment method includes: preparing the antibody 6A12 into a 1 mg / mL solution, and preparing NHS-LC-biotin into a 60 mg / mL solution with DMSO; taking 200 μL of the 1 mg / mL antibody 6A12 solution, adding 10 μL of the 60 mg / mL NHS-LC-biotin solution; after mixing and placing at room temperature for 30 minutes, adding 50 μg of 500 mM Tris solution (pH 9.0) was used to terminate the reaction; finally, a large amount of 1×PBS buffer solution at pH 7.4 was added, and centrifuged using a centrifugal column with an exclusion limit of 30KD to remove excess biotin molecules and balance the buffer system; 7) Washing the plate: After the incubation is completed, the liquid in the wells was discarded, and the plate was washed three times with 1×PBST, and 300 μL of the sample was added. After standing for 40 seconds, the liquid in the wells was discarded and the liquid in the wells was patted dry on a flat paper; 8) Adding SA-HRP: 100×SA-HRP (horseradish peroxidase labeled streptavidin, purchased from Wuhan Sanying Biotechnology Co., Ltd., catalog number SA00001-0) concentrate was diluted 100 times, and 100 μL / well was added to the ELISA plate in sequence, covered with a cover film, and incubated at 37°C for 0.5h; 9) Washing: After the incubation is completed, discard the liquid in the well, wash the plate three times with 1×PBST, add 300μL of sample, let it stand for 40s, then discard the liquid in the well, and pat the liquid in the well dry on a flat paper; 10) Add TMB colorimetric solution: Add 3,3',5,5'-tetramethylbenzidine (TMB) colorimetric solution to the ELISA plate at 100μL / well, cover with a cover film, and incubate at 37℃ for 15min; 11) Reading: After the incubation is completed, take out the ELISA plate, add 50μL of stop solution (1mol / L hydrochloric acid) to each well, and immediately read with an ELISA reader. The concentration of mouse IL-2 protein is used as the horizontal axis, and the correction value of the absorbance value is Y1 (Y1=OD. 450nm -OD 630nm ) as the ordinate, and the standard curve was obtained by using the four-parameter fitting of the Logistic curve. The lowest mouse IL-2 concentration with an average absorbance value greater than three times the average absorbance value of the blank control was taken as the sensitivity of the double antibody sandwich ELISA system. Figure 5 and Table 4.

[0097] Table 4 Sensitivity test data of double antibody sandwich ELISA system based on antibodies 2A5 and 6A12

[0098]

[0099] The above results show that the double antibody sandwich ELISA established based on antibodies 2A5 and 6A12 for detecting mouse IL-2 protein has good linearity in the protein concentration range of 0-2000pg / mL, with a sensitivity of 54.85pg / mL, which can achieve high-sensitivity and high-reliability detection of trace IL-2 protein in the samples to be tested.

[0100] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An antibody for detecting mouse interleukin-2, characterized in that Selected from the first antibody or the second antibody, wherein: The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region of the first antibody are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.

2. The antibody for detecting mouse interleukin-2 according to claim 1, characterized in that The amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; The amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.

17.

3. The antibody for detecting mouse interleukin-2 according to claim 2, characterized in that The amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6; The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.

16.

4. The antibody for detecting mouse interleukin-2 according to claim 3, characterized in that The light chain constant region of the first antibody and the second antibody is a κ chain, and the heavy chain constant region is an IgG1 type.

5. The antibody for detecting mouse interleukin-2 according to claim 1, characterized in that The first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; The antigen binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.

6. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the first antibody or the second antibody according to any one of claims 1 to 5.

7. An antibody pair for detecting mouse interleukin-2, characterized in that: The method comprises the first antibody and the second antibody as described in any one of claims 1 to 5.

8. Use of the antibody for detecting mouse interleukin-2 according to any one of claims 1 to 5 or the antibody pair for detecting mouse interleukin-2 according to claim 7 in the preparation of a reagent or kit for detecting mouse interleukin-2.

9. A detection reagent or kit for detecting mouse interleukin-2, characterized in that: The detection reagent or kit comprises the antibody for detecting mouse interleukin-2 according to any one of claims 1 to 5 or the antibody pair for detecting mouse interleukin-2 according to claim 7.

10. The detection reagent or kit for detecting mouse interleukin-2 according to claim 9, characterized in that: The detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, and the second antibody modified with a detectable label serves as a detection antibody.